Endocrine Abstracts

The increasing global prevalence of obesity requires urgent intervention to limit the anticipated surge of associated cardiometabolic morbidity and mortality. The energy sensor AMP-activated protein kinase (AMPK) is one proposed target for treating metabolic disorders and is downregulated in adipose tissue of obese insulin resistant individuals. Given the strong relationship between metabolic syndrome and overactivity of the renin-angiotensin-aldosterone system (RAAS) we inves...